Byoung Chul Cho
0000-0002-5562-270X
Publication & Citation Trends
Publications
0 total
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.
Cited by 1
Semantic Scholar
Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA Study.
Cited by 0
Semantic Scholar
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.
Cited by 1
Semantic Scholar
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
Cited by 39
Semantic Scholar
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
Cited by 70
Semantic Scholar
Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas.
Cited by 16
Semantic Scholar
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study
Cited by 0
Semantic Scholar
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
Cited by 92
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(997)
Cancer Immunotherapy and Biomarkers
(366)
Lung Cancer Research Studies
(307)
Colorectal Cancer Treatments and Studies
(255)
Lung Cancer Diagnosis and Treatment
(179)
Affiliations
Ulsan College
Hebron University
Universitat Autònoma de Barcelona
University Health Network
Memorial Sloan Kettering Cancer Center